The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Tumor genomic analysis for 128 renal cell carcinoma (RCC) patients receiving first-line everolimus: Correlation between outcome and mutations status in MTOR, TSC1, and TSC2.
 
Martin Henner Voss
Honoraria - Novartis
Consulting or Advisory Role - Calithera Biosciences; Exelixis; GlaxoSmithKline; Natera; Novartis
Research Funding - Bristol-Myers Squibb; Pfizer
Travel, Accommodations, Expenses - Novartis; Takeda
 
David Chen
No Relationships to Disclose
 
Mahtab Marker
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Jianing Xu
No Relationships to Disclose
 
Parul Patel
No Relationships to Disclose
 
Xia Han
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
James Hsieh
Honoraria - Chugai Pharma
Consulting or Advisory Role - Chugai Pharma; Eisai; Novartis
Research Funding - CGI; Novartis; Pfizer
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb